Company profile
BioMark Diagnostics Inc.
OTC: BMKDF · Healthcare · Medical - Diagnostics & Research
Canadian filerHQ Richmond, BCReports USD
#1044 of 1,422 Healthcare companies by revenue33rd-percentile growth
EA Score
——FH —DQ —GM —SS 45
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, 3-yr revenue growth · ↓ Piotroski F, net margin
Methodology →Revenue TTM
$43.2k
Rev growth YoY (TTM)
-61.0%
Net income (FY)
-$1.4M
Employees
9
as of 2026-08-20
Market cap
$45.2M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$110.8k154.2k CAD2025
Net income-$1.4M-1.9M CAD2025
Operating income-$1.4M-1.9M CAD2025
Total assets$2.2M3.1M CAD2025
Liabilities$969.2k1.4M CAD2025
Equity$1.2M1.7M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioMark Diagnostics Inc.’s revenue?
BioMark Diagnostics Inc. booked $110.8k in FY2025 revenue, contracting 8.4% year over year — slower than 67% of Healthcare companies we track, at a -1249.7% net margin.
Peers · Healthcare
Creative Edge Nutrition, Inc.——Forza Innovations Inc.——Biostax Corp.——Finch Therapeutics Group, Inc.——Meridian Holdings, Inc.——Profusa, Inc. Common Stock9DKey facts
CEORashid Ahmed Maula Bux
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersRichmond, BC
ExchangeOTC: BMKDF
Employees9
IPO date2015-03-23
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.